Eris Lifesciences to hold Analyst & Investor Call on Feb 13, 2026
Eris Lifesciences Limited will host an analyst and investor conference call on February 13, 2026, at 5:30 PM IST. The call will discuss the unaudited financial results for the quarter and nine months ended December 31, 2025.
This is a standard procedural announcement for an upcoming investor call to discuss financial results. It does not contain new financial information or strategic decisions that would significantly impact the company's stock or operations.
The announcement is a routine intimation about a scheduled investor call and does not contain any financial performance data or forward-looking statements that would indicate a positive or negative sentiment.
Eris Lifesciences Limited has announced an upcoming conference call for analysts and investors. This call is scheduled to take place on Friday, February 13, 2026, at 05:30 PM IST.
The purpose of this conference call is to discuss the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025. This information follows a previous intimation regarding the Board of Directors meeting to consider and approve these financial results, which was dated February 06, 2026.
Details for joining the call are available on the Company’s website and were attached to the announcement. Interested participants can pre-register for the Zoom call via a provided link. The company looks forward to the participation of analysts and investors.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.